Novartis has launched the FocalView app, an ophthalmic digital research platform designed to allow researchers to track disease progression by collecting real-time data reported from consenting patients.
By adapting the design of clinical trials for patients’ daily routines, the app may reduce barriers to study participation, the company said in a press release.
The app will help patients complete assessments and gain feedback on their visual function, including changes over time. It can also provide researchers with real-world, patient-reported data to create more flexible and accessible
Uncategorized